Skip to main content
Clinical Trials/NCT02105532
NCT02105532CompletedPhase 2

A Multi-centre, Feasibility, Cluster Randomised Controlled Trial Comparing Restrictive Versus Liberal Blood Transfusion Strategies in Adult Patients Admitted With Acute Upper Gastrointestinal Bleeding

Dr Vipul Jairath1 site in 1 country936 target enrollmentStarted: September 1, 2012Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
936
Locations
1
Primary Endpoint
Adherence to the study protocol

Study Overview

Brief Summary

Aim: To evaluate the feasibility and safety of a restrictive versus liberal red blood cell (RBC) transfusion policy in adult patients admitted with Acute Upper Gastrointestinal Bleeding (AUGIB) in order to inform the design of a definitive phase III randomised controlled trial.

Detailed Description

Trial overview: TRIGGER is a pragmatic trial aiming to recruit adult patients admitted with all cause AUGIB (non-variceal and variceal). The study will take place in six United Kingdon hospitals and they will be randomly allocated to a transfusion policy at the cluster level; three sites will be allocated to a restrictive transfusion policy and three to a liberal transfusion policy. Given the challenges that will be involved in early recruitment and cross-speciality care, a feasibility study is essential to determine whether a sufficient proportion of eligible patients can be recruited into the trial and that clinicians can adhere to the allocated transfusion policy. Recruitment will operate for 6 months in total. The investigators will compare recruitment rate, protocol adherence, clinical characteristics of patients recruited, exposure to RBC transfusions and the difference in Hb concentrations between the restrictive and liberal transfusion policies. The investigators will collect important clinical outcomes which the investigators anticipate being central to the phase III trial, including 28-day mortality, further bleeding rates and serious adverse events between the restrictive and liberal transfusion policies. The investigators will also collect data to enable us to plan a health economic evaluation and quality of life assessment for the phase III trial.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adults aged 18 or over years presenting with AUGIB, defined by haematemesis or melaena.

Exclusion Criteria

  • •Patients with whom the responsible clinician considers there is a need for immediate RBC transfusion prior to obtaining or regardless of the initial Hb result due to severity of bleeding.
  • •Existing hospital in-patients who develop AUGIB.

Arms & Interventions

Restrictive Transfusion Policy

Active Comparator

Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.

Intervention: Restrictive transfusion policy (Other)

Liberal Transfusion Policy

Active Comparator

Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.

Intervention: Liberal Transfusion Policy (Other)

Outcomes

Primary Outcomes

Adherence to the study protocol

Time Frame: up to 28 days

Protocol adherence will be measured over time, to determine if adherence rates improve. Adherence rates will also be compared between transfusion arms.

Secondary Outcomes

  • Further Bleeding(up to 28 days)

Investigators

Sponsor
Dr Vipul Jairath
Sponsor Class
Other Gov
Responsible Party
Sponsor Investigator
Principal Investigator

Dr Vipul Jairath

Research Fellow in Gastroneterology

NHS Blood and Transplant

Study Sites (1)

Loading locations...

Similar Trials